Chun Lai Beats Artemisia selengensis
Release time:
2023-05-11
Artemisia selengensis is a unique herbaceous plant that grows on the bank of the southern Anhui River and is also the love of people in their hometown. A pure fried bacon with artemisia selengensis and a plate of fresh and refreshing fried artemisia selengensis are essential seasonal delicacies for restaurants and families. whenever foreign guests visit, we will strongly recommend this delicacy to highlight the flavor of our hometown.
I have long planned to pick wild Artemisia selengensis in person, so one weekend, I asked a few experienced colleagues to "fight" Artemisia selengensis together. Along the way to the river, there were bumpy mud roads. After walking for about one kilometer, I found a large area of lush wild plants not far from the side of the road. The stems and leaves looked like Artemisia quinoa. I couldn't help but stop, thinking, since it can be harvested here, why continue to walk such a lousy road to the riverside? Besides, if it is really Artemisia selengensis, how come it is so luxuriant and no one picks it? I was not sure, and I sniffed a few of them. It did smell a bit like Artemisia selengensis, but it seemed that there was something different, so I pulled a handful and showed it to my colleagues. Colleagues looked at the "Artemisia selengensis" in my hand and smiled: "This is bitter artemisia, not delicious, astringent." Then how exactly should Artemisia selengensis be distinguished? Colleagues explained: "It's very simple, the reddish stem of wild Artemisia selengensis is the main feature, and the stem of Artemisia selengensis in the greenhouse is very fat, long, and green, very shiny, which can be seen at a glance." Well, I 've never picked Artemisia selengensis before. I really made a fool of myself. This is the taste of "no distinction between grains.
finally came to the river, the winter wilderness has shown a large area of green, along the river bank to the distance. There are not many people who play the artemisia, scattered in the green. Colleagues said that it is the best time to fight Artemisia seleniae today. After the rain, there are few people, and Artemisia seleniae growing from cracks on the ground can easily be pulled out by roots. Having said that, I am really a layman. I still can't figure out what is the most suitable for eating and what should be paid attention to when "fighting. Looking at my clumsy appearance, my colleague enthusiastically taught me some basic common sense in her opinion. For example, the green leaves are the new ones, and the best ones are the ones that grow in the cracks, and the tender roots can be eaten. With her experience, I finally found the feeling, so everyone chose one direction and acted separately. Each person took a plastic bag and enjoyed the spring sunshine while picking wild vegetables. It was really pleasant. Unconsciously, everyone picked a big bag of tender, raw Artemisia selengensis.
On the return trip, looking at the mud on my feet and the hair blown by the river wind, I really felt close contact with nature. In recent years, these wild vegetables, which grow naturally in the mountains, have been more and more infatuated with people. Perhaps, this can be regarded as a return to nature mentality of human beings. (Song Danlin)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31